Cost of Oral Cyclophosphamide Without Insurance
I cannot provide specific cash pricing for oral cyclophosphamide without insurance coverage, as the evidence provided does not contain pharmaceutical pricing information.
What the Evidence Does Tell Us About Cost Considerations
The KDIGO 2024 guidelines explicitly state that oral cyclophosphamide is less expensive than intravenous cyclophosphamide 1. The guidelines note that while rituximab is typically more expensive than cyclophosphamide overall, secondary costs for cyclophosphamide (including infusions and monitoring) can make total costs similar 1.
Key Cost-Related Clinical Considerations
For patients where cost is an important factor, the KDIGO 2024 guidelines specifically recommend oral cyclophosphamide over intravenous administration 1.
Dosing for a 70kg Adult with Vasculitis
For your specific scenario of a 70kg adult with vasculitis, the recommended oral cyclophosphamide dosing would be 1:
- Standard dose: 2 mg/kg/day = 140 mg/day for 3 months
- If patient is ≥60 years old: 1.5 mg/kg/day = 105 mg/day
- If patient is ≥70 years old: 1.0 mg/kg/day = 70 mg/day
- Duration: 3-6 months for remission induction
This translates to approximately:
- 12,600-25,200 mg total cumulative dose for a standard 3-6 month course at 140 mg/day
- 6,300-12,600 mg total cumulative dose for a 70-year-old at 70 mg/day
Where to Find Actual Pricing
To obtain specific cash prices without insurance, you should:
- Contact local retail pharmacies directly (prices vary significantly by location and pharmacy)
- Check online pharmacy discount programs (GoodRx, RxSaver, etc.)
- Inquire about generic formulations, which are substantially less expensive than brand-name versions
- Consider patient assistance programs from pharmaceutical manufacturers
The evidence confirms oral cyclophosphamide is the most cost-effective route of administration compared to intravenous formulations 1, but actual dollar amounts require direct pharmacy pricing inquiries.